Michael Barnett
机构: The University of Sydney / Brain and Mind Centre
每年引用次数
引用次数
引用: 20,291
H-指数: 70
I10-指数 : 195
出版物: 609
Treatment persistence in the Australian relapsing remitting MS population: Results from the MSBase Registry
T Spelman , M Slee , VG Jokubaitis , C Shaw
Multiple Sclerosis Journal 18 ( 5)
2012
Comparison of MS outcomes after Switching to Natalizumab versus staying on Interferon-beta or glatiramer
M Trojano , H Koendgen , C Boz , A Lugaresi
Multiple Sclerosis Journal 22
2016
Peripheral nervous system involvement in MOG antibody-associated demyelination
S W Reddel , J Parratt , M Monif , F Brilot
Multiple Sclerosis Journal 25 94 -95
2019
Using single cell DNA-seq to decipher disease mechanisms for MS
SJ Leslie , A Motyer , A Shiu , A Harding
Multiple Sclerosis Journal 26 ( 3)
2020
Efficacy and Safety of Natalizumab in Multiple Sclerosis: Interim Observational Program Results from an Australian Cohort.
S Hodgkinson , M Slee , J Lechner-Scott , C Kneebone
Multiple Sclerosis Journal 22 ( 3)
2016
Comparison of efficacy and persistence of first line fingolimod vs interferon-beta/glatiramer in the presence of prior disease activity
T Spelman , G Izquierdo , R Alroughani , R Fernandez-Bolanos
Multiple Sclerosis Journal 21
2015
Risk of early relapse following switch to oral agents for multiple sclerosis
M Trojano , E Havrdova , A Lugaresi , S Hodgkinson
Multiple Sclerosis Journal 21
2015
EXPOSURE TO INTERFERON-β THERAPY IN EARLY PREGNANCY: A LITERATURE REVIEW OF PREGNANCY OUTCOMES IN WOMEN WITH MULTIPLE SCLEROSIS
S Hughes , T Spelman , O Gray , C Boz
Journal of Neurology, Neurosurgery, and Psychiatry 83
2
2012
Paraneoplastic brain stem encephalitis in a woman with anti-Ma2 antibody
M Barnett , J Prosser , I Sutton , GM Halmagyi
Journal of Neurology, Neurosurgery & Psychiatry 70 ( 2) 222 -225
49
2001
MS FIRST-utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term
J Haartsen , T Spelman , J Baker , S Agland
Multiple Sclerosis Journal 23 403 -404
2017
MSFIRST-utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term
J Haartsen , T Spelman , J Baker , S Agland
Multiple Sclerosis 22 ( Supp: 3) 342 -343
2016
Fingolimod therapy in real world relapsing ms patients: cognition, quantitative mri and deep gray matter quantitative susceptibility mapping
H Beadnall , B Weinstock-Guttman , C Wang , J Hagemeier
MULTIPLE SCLEROSIS JOURNAL 26 ( 3_ SUPPL) 533 -534
2020
Medulla oblongata volume measured from clinical routine T2-FLAIR scans is associated with disability progression in a multiple sclerosis real-world dataset
N Bergsland , M Barnett , B Weinstock-Guttman , H Butzkueven
MULTIPLE SCLEROSIS JOURNAL 28 ( 3_ SUPPL) 289 -290
2022
Lateral ventricular atrophy measurements agree better than whole brain measures across centers and measurement techniques
M Dwyer , N Bergsland , D Horakova , M Vaneckova
MULTIPLE SCLEROSIS JOURNAL 23 935 -936
2017
A multicentre study of quantitative susceptibility mapping in sub-cortical deep gray matter structures in relapsing multiple sclerosis
R Zivadinov , F Schweser , C Dawes , J Hagemeier
MULTIPLE SCLEROSIS JOURNAL 22 222 -222
2016
Are stable MS patients who stop their disease-modifying therapy (DMT) at increased risk for relapses and disability progression compared to patients who continue on DMTs? A propensity-score matched analysis of the MSBase registrants
I Kister , Tim Spelman , Raed Alroughani , Jeannette Lechner-Scott
Multiple Sclerosis 21 ( Supp: 11) 17 -18
3
2015
The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis
JWL Brown , A Coles , D Horakova , E Havrdova
Multiple Sclerosis Journal 23 ( Suppl. 3) 32 -34
2
2017
Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon â-1a
T Kalincik , JW Brown , N Robertson , M Willis
Multiple Sclerosis 22 ( Supp: 3) 829 -832
2
2016
Comparative efficacy of switch to natalizumab of fingolimod in active relapsing. remitting multiple sclerosis
T Kalincik , D Horakova , T Spelman , V Jokubaitis
MULTIPLE SCLEROSIS 20 195 -196
2
2014
Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis
MVH Le , C Malpas , S Sharmin , D Horakova
Multiple Sclerosis Journal 24 135 -137
2018